# A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

> **NCT05076175** · PHASE2,PHASE3 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 120 (estimated)

## Conditions studied

- Colitis, Ulcerative

## Interventions

- **DRUG:** Ozanimod

## Key facts

- **NCT ID:** NCT05076175
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-30
- **Primary completion:** 2026-05-22
- **Final completion:** 2031-08-14
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05076175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05076175, "A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05076175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*